Draft Regulations

Draft Regulation

Podiatry Act
(R.S.Q., c. P-12)

Podiatrists
— Medications
— Amendments

Notice is hereby given, in accordance with sections 10 and 11 of the Regulations Act (R.S.Q,. c. R-18.1), that the Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients was adopted by the Office des professions du Québec.

The Regulation, the text of which appears below. may be submitted to the Government, which pursuant to section 13 of the Professional Code (R.S.Q., c. C-26), may approve it, with or without amendment, upon the expiry of 45 days following this publication.

The purpose of the Regulation is to update the list of medications that podiatrists may use in the practice of their profession or administer or prescribe to their patients and determine the conditions according to which they may administer and prescribe such medications.

In order to be appropriately advised when updating the list, the Office formed a panel of experts consisting of four members, including a representative of the Office acting as coordinator and three experts including a podiatrist, a physician and a pharmacist, designated by the Office after consulting the Ordre des podiatres du Québec. the Collège des médecins du Québec and the Ordre des pharmaciens du Québec.

The Conseil consultatif de pharmacologie, the Ordre des podiatres du Québec, the Collège des médecins du Québec and the Ordre des pharmaciens du Québec have also been duly consulted by the Office with respect to the update.

The Regulation, which is an update of the Regulation currently in force, will have no impact on businesses, small and medium-sized businesses or other.

Further information on the proposed regulation may be obtained by contacting Lucie Boissonneault, research officer, or France Lesage, advocate, Office des professions du Québec, 800, place D'Youville, 10e étage, Québec (Québec) GIR 5Z3, by telephone at (418) 643-6912 or 1 800 643-6912 or by fax at (418) 643-0973.

Any interested person having comments to make is asked to send them in writing, before the expiry of the 45-day period, to the Chairman of the Office, at the abovementioned address. Those comments will be forwarded by the Office to the Minister responsible for the administration of legislation respecting the professions; they may also be forwarded to the professional orders involved and to the interested persons, departments and agencies.

JEAN-K. SAMSON,
Chairman of the
Office des professions du Québec

Regulation to amend the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients*

Podiatry Act
(R.S.Q., c. P-12, s. 12)

1. Section 1 of the Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients is amended

(1) by adding the words "or in Schedule II subject to the conditions prescribed in this Regulation" at the end;

(2) by adding the following paragraphs at the end:

* The Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients, approved by Order in Council 1057-91 dated 24 July 1991 (1991, *G.O.* 2, 3231) has not been amended since.

"A podiatrist, who administers or prescribes to his patients the medications described in Schedule II that are not medications described in Schedule I, shall hold a certificate issued by the Ordre des podiatres du Québec acknowledging that he received university training in podiatric medicine in the last five years, comprising a minimum of 1145 hours apportioned as follows:

(1) 540 hours in anatomy-physiology;

(2) 90 hours in biochemistry;

(3) 105 hours in microbiology;

(4) 275 hours in general pathologies;

(5) 90 hours in basic pharmacology;

(6) 45 hours in clinical pharmacology.

Before he may administer or prescribe to his patients the medications described in Schedule II that are not medications described in Schedule I, a podiatrist whose training referred to in subparagraphs 1 to 6 of the second paragraph was received more than five years ago shall successfully complete the continuing education activities determined by the Ordre des podiatres du Québec pursuant to paragraph *o* of section 94 of the Professional Code (R.S.Q., c. C-26; 2000, c. 13, s. 20) and hold a certificate issued by the Order acknowledging that the activities were successfully completed.".

2. Section 2 is revoked.

3. The following Schedules are substituted for Schedule I:

"**SCHEDULE I**

Note: medications without specification are intended for topical application.

Substances	Specification
Acetaminophen	Pharmaceutical forms intended for oral and rectal administration
Acetic, glacial acid	
Acetylsalicylic, acid	Pharmaceutical forms intended for oral administration
Almond, sweet oil	
Aluminium and its salts	
Amcinonide	Quantity limited for 30 days
Amino acids	
Anthralin (dithranol)	
Bacitracin and its salts	
Beclomethasone and its salts	
Benzalkonium	
Benzocaine	
Betamethasone benzoate	
Betamethasone dipropionate	Quantity limited for 30 days
Betamethasone valerate	
Bupivacaine and its salts	Pharmaceutical forms intended for administration by injection for local use only
Calcipotriol	
Calcium acetate	
Camphor	
Cantharin	
Capsaicin	
Cetirizine hydrochloride	Pharmaceutical form intended for oral administration
Cetrimide	
Chlorhexidine and its salts	
Chlorphenesin	
Chlorprocaine hydrochloride	Pharmaceutical form intended for administration by injection for local use only
Ciclopirox olamine	
Cinchocaine	
Clioquinol (iodochlorhydroxyquin)	

Substances	Specification
Clobetasol proprionate	Quantity limited for 30 days
Clobetasone butyrate	
Clotrimazole	
Collagenase	
Colloidal oatmeal	
Dakin's solution	
Deoxyribonuclease	
Desonide	
Desoximetasone	Quantity limited for 30 days
Dichloracetic acid	
Diethylamine salicylate	
Diflucortolone valerate	Quantity limited for 30 days
Diphenhydramine	Pharmaceutical forms intended for oral and topical administration
Econazole nitrate	
Epinephrine (adrenaline)	Pharmaceutical forms for the emergency treatment of anaphylactic reactions in the form of self-injector or ampoule
	Pharmaceutical form associated with local anaesthetics
Erythromycin	
Ethyl chloride	
Fibrinolysin	
Flumetasone pivalate	
Fluocinode	Quantity limited for 30 days
Fluocinolone acetonide	Quantity limited for 30 days
Formalin	
Framycetin sulfate	
Fusidic acid	

Substances	Specification
Gentamicin sulfate	
Gentian, violet	
Gramicidin	
Halcinodide	Quantity limited for 30 days
Hexachlorophene	
Hydrocortisone and its salts	
Hydroxyzine hydrochloride	Pharmaceutical form intended for oral administration
Iodine tincture	
Isopropyl myristate	
Ketoconazole	
Lactic acid	
Lanolin	
Lidocaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only
Loratadine	Pharmaceutical form intended for oral administration
Mafenide and its salts	
Magnesium salicylate	
Menthol	
Mepivacaine	Pharmaceutical form intended for administration by injection for local use only
Methyl salicylate	
Methylpolysiloxanes	
Methylprednisolone acetate	
Miconazole nitrate	
Mineral and vegetal tar	
Mineral oil	

Substances	Specification
Mometasone furorate	
Mupirocin	
Neomycin sulfate	
Nystatin	
Oxiconazole	
Phenol	
Podophyllin	
Polymyxin B sulfate	
Povidone iodine	
Pramoxine	
Prilocaine	Pharmaceutical forms intended for topical application and administration by injection for local use only
Procaine	Pharmaceutical form intended for administration by injection for local use only
Resorcinol and its salts	
Salicylic acid	
Silicone	
Silver nitrate	
Silver sulfadiazine	
Sodium thiosulfate	
Sulphur, colloidal, precipitate or sublimate	
Synthetic sebum	
Tazarotene	
Terbinafine	
Tetracaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only
Tioconazole	
Tolnaftate	
Triamcinolone acetonide	Quantity limited for 30 days
Trichloroacetic acid	
Triethanolamine salicylate	
Urea	Pharmaceutical form intended for topical application, with a concentration of 30% or less
White petroleum jelly	
Zinc oxide	

SCHEDULE II

Note: medications without specification are intended for topical application.

Substances	Specifications
Acetaminophen	Pharmaceutical form intended for oral and rectal administration
Acetaminophen and codeine (in combination)	Pharmaceutical form intended for oral administration containing 30 mg and less of codeine per tablet
Acetic, glacial acid	Quantity limited to 24 tablets/72 hours
Acetylsalicyclic acid	Pharmaceutical form intended for oral administration
Almond, sweet oil	
Aluminium and its salts	
Amcinonide	Quantity limited for 30 days
Amino acids	
Anthralin (dithranol)	
Bacitracin and its salts	
Beclomethasone and its salts	
Benzalkonium	
Benzocaine	

Substances	Specifications
Betamethasone benzoate	
Betamethasone dipropionate	Pharmaceutical forms intended for topical application and administration per intradermal or intramuscular injection
	Quantity limited for 30 days
Betamethasone valerate	
Bleomycin sulfate	Pharmaceutical form injectable in the plantar lesion without exceeding 0.8 unit up to a maximum of 5 units per treatment
Bupivacaine and its salts	Pharmaceutical form intended for administration by injection for local use only
Calcipotriol	
Calcium acetate	
Camphor	
Cantharin	
Capsaicin	
Celecoxib	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Cetirizine hydrochloride	Pharmaceutical form intended for oral administration
Cetrimid	
Chlorhexidine and its salts	
Chlorphenesin	
Chlorprocaine hydrochloride	Pharmaceutical form intended for administration by injection for local use only
Ciclopirox olamine	
Cinchocaine	
Clioquinor (iodochlorhydroxyquin)	
Clobetasol proprionate	Quantity limited for 30 days
Clobetasone butyrate	
Clotrimazole	
Collagenase	
Colloidal oatmeal	
Dakin's solution	
Deoxyribonuclease	
Desonide	
Desoximetasone	Quantity limited for 30 days
Dichloracetic acid	
Diclofenac, potassic and sodic	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Diethylamine salicylate	
Diflucortolone valerate	Quantity limited for 30 days
Dyphenhydramine	Pharmaceutical forms intended for oral administration and administration per intramuscular, subcutaneous or intradermal injection
Econazole nitrate	
Epinephrine (adrenaline)	Pharmaceutical forms for the emergency treatment of anaphylactic reactions in the form of auto-injector or vial
	Pharmaceutical form associated with local anaesthetics
Erythromycin	
Ethyl chloride	
Fibrinolysin	
5-fluorouracil	0.1% pharmaceutical form intended for topical application in the case of plantar warts resisting to first-line treatments
Flumetasone pivalate	
Fluocinode	Quantity limited for 30 days

Substances	Specifications
Fluocinolone acetonide	Quantity limited for 30 days
Formaline	
Framycetin sulfate	
Fusidic acid	
Gentamicin sulfate	
Gentian, violet	
Gramicidin	
Halcinodide	Quantity limited for 30 days
Hexachlorophene	
Hydrocortisone and its salts	
Hydroxyzine hydrochloride	Pharmaceutical form intended for oral administration
Ibuprofen	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Iodine tincture	
Isopropyl myristate	
Ketoconazole	
Lactic acid	
Lanolin	
Lidocaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only
Loratadine	Pharmaceutical form intended for oral administration
Mafenide and its salts	
Magnesium salicylate	
Menthol	
Mepivacaine	Pharmaceutical form intended for administration by injection for local use only
Methyl salicylate	
Methylpolysiloxanes	
Methylprednisolone acetate	Pharmaceutical forms intended for topical application and administration by injection for local use only
Miconazole nitrate	
Mineral and vegetal tar	
Mineral oil	
Mometasone furorate	
Mupirocin	
Naproxen	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days
Neomycin sulfate	
Nystatin	
Oxiconazole	
Phenol	
Podophyllin	
Polymyxin B sulfate	
Povidone iodine	
Pramoxine	
Prilocaine	Pharmaceutical forms intended for topical application and administration by injection for local use only
Procaine	Pharmaceutical form intended for administration by injection for local use only
Resorcinol and its salts	
Rofecoxib	Pharmaceutical form intended for oral administration
	Quantity limited for 30 days

Substances	Specifications
Salicylic acid	
Silicone	
Silver nitrate	
Silver sulfadiazine	
Sodium thiosulfate	
Sulphur, colloidal, precipitate or sublimate	
Synthetic sebum	
Tazarotene	
Terbinafine	
Tetracaine and its salts	Pharmaceutical forms intended for topical application and administration by injection for local use only
Tioconazole	
Tolnaftate	
Triamcinolone acetonide	Quantity limited for 30 days
Triamcinolone hexacetonide	Pharmaceutical forms intended for administration by intramuscular or intradermal injection Quantity limited for 30 days
Trichloroacetic acid	
Triethanolamine salicylate	
Urea	Pharmaceutical form intended for topical application, with a concentration of 30% or less
White petroleum jelly	
Zinc oxide".	

4. This Regulation comes into force on the fifteenth day following the date of its publication in the *Gazette officielle du Québec*.

4794